Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_DeferredRevenueCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of receivable from development, regulatory, and sales milestone payments if certain milestones are successfully achieved.

+ References

No definition available.

+ Details

Name:	zbio_CollaborativeArrangementDevelopmentRegulatoryAndSalesMilestonePaymentsReceivableMaximum
Namespace Prefix:	zbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of cash inflow from milestone payment received pursuant to the agreement.

+ References

No definition available.

+ Details

Name:	zbio_CollaborativeArrangementProceedsFromMilestonePayments
Namespace Prefix:	zbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of receivable from sales milestone payments if certain milestones are successfully achieved.

+ References

No definition available.

+ Details

Name:	zbio_CollaborativeArrangementSalesMilestonePaymentsReceivableMaximum
Namespace Prefix:	zbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount of transaction price receivable under the collaborative agreement.

+ References

No definition available.

+ Details

Name:	zbio_CollaborativeArrangementTransactionPrice
Namespace Prefix:	zbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of cash inflow from upfront payment received pursuant to the agreement.

+ References

No definition available.

+ Details

Name:	zbio_CollaborativeArrangementUpfrontPaymentReceived
Namespace Prefix:	zbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of development milestone payable in connection with the agreement during the period.

+ References

No definition available.

+ Details

Name:	zbio_LicenseAndOptionAgreementsDevelopmentMilestonePayable
Namespace Prefix:	zbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Research and development costs incurred for global development reimbursed per terms of the license and collaboration agreement.

+ References

No definition available.

+ Details

Name:	zbio_ResearchAndDevelopmentExpensesReimbursed
Namespace Prefix:	zbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=zbio_LicenseAgreementWithBristolMyersSquibbMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=zbio_NovationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=zbio_LicenseAgreementWithZaiLabsHongKongLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=zbio_ViridianAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

License and Collaboration Revenue (Details) - USD ($) $ in Thousands	1 Months Ended				3 Months Ended			9 Months Ended
	Sep. 30, 2026	Jan. 31, 2025	Oct. 31, 2024	Aug. 31, 2023	Sep. 30, 2026	Sep. 30, 2025	Mar. 31, 2025	Sep. 30, 2026	Sep. 30, 2025
License and Collaboration Revenue
Amount of upfront cash payment received									$ 75,000
Revenue					$ 10,000			$ 11,000	10,000
Deferred revenue	$ 2,031				2,031			2,031
BMS Agreement
License and Collaboration Revenue
Amount of upfront cash payment received				$ 50,000
Proceeds from milestone payments	10,000
Maximum amount of payments receivable				69,500
Sales milestone payments receivable				$ 70,000
Reduction in research and development costs pertaining to reimbursed global development costs					900	$ 1,300		2,800	4,200
Revenue					10,000	0		10,000	0
Deferred revenue	$ 2,000				2,000			2,000
Tenacia Novation Agreement
License and Collaboration Revenue
Amount of upfront cash payment received			$ 5,000
Maximum amount of payments receivable			$ 85,000
Revenue					$ 0	$ 0		$ 1,000	$ 0
License Agreement with Zai Lab (Hong Kong) Limited
License and Collaboration Revenue
Amount of upfront cash payment received		$ 10,000
Maximum amount of payments receivable		117,000
Agreement transaction price							$ 10,000
Viridian Agreement
License and Collaboration Revenue
Development milestone expense payable		$ 21,000